and CONKO-004, included only patients with pancreas cancer 13 - 15 and the PRODIGE trial included only patients with malignant glioma. 16 Two additional studies evaluated thromboprophylaxis specifically in multiple myeloma. 17 , 18 Mixed Solid
Search Results
Thein Hlaing Oo
should recommend outpatient thromboprophylaxis to select patients, including those at high risk based on the risk score, those with pancreas cancer initiating chemotherapy, and those with myeloma initiating IMid- (immunomodulatory drug) based combination
Andrew H. Ko and Margaret A. Tempero
– 755 . 5 Burris HA 3rd Moore MJ Andersen J . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413
Anirban Maitra
cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States . Cancer Res 2014 ; 74 : 2913 – 2921 . 2. Bailey P Chang DK Nones K . Genomic analyses identify molecular subtypes of
Shane Lloyd, Daniela L. Buscariollo, Cary P. Gross, Danil V. Makarov, and James B. Yu
, the average enrollment for trials of that cancer type was imputed. Per cancer type, total planned enrollment was missing most often for pancreas cancer trials (13 of 40; 33%), and least often for testicular cancer trials (0 of 6; 0%). Although imputing
Pelin Cinar and Andrew H. Ko
. Philip PA Mooney M Jaffe D . Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment . J Clin Oncol 2009 ; 27 : 5660 – 5669 . 6. Ko AH . Locally advanced pancreatic cancer: is there a
Parvin F. Peddi and Andrea Wang-Gillam
-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer . Radiother Oncol 2011 ; 99 : 114 – 119 .
Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, and Yaacov Richard Lawrence
with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413 . 4. Conroy T Desseigne F Ychou M . FOLFIRINOX versus gemcitabine for metastatic pancreatic
Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor
assigned a probability equal to one. We performed a similar calculation for both ovarian and pancreas cancers, determined the overall probability of each diagnosis from their frequencies in the population (1.37% and 1.48%, respectively), 30 and calculated
Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff
. Pancreas 2011 ; 40 : 426 – 432 . 3. Burris HA 3rd Moore MJ Andersen J . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997
